Tumor-associated antigen-derived peptides presented on MHC class II (TAA-MHC II) (TAA-MHC II)

Tumor-associated antigen (TAA)-derived peptides presented on MHC class II molecules are a specialized class of therapeutic targets that facilitate the recognition of cancer cells by CD4+ T-helper cells. Unlike MHC class I molecules, which are expressed on all nucleated cells and present endogenous antigens to CD8+ T cells, MHC class II molecules (HLA-DR, HLA-DQ, and HLA-DP) are primarily expressed on professional antigen-presenting cells and certain tumor types (Nature Reviews Cancer, 2017). These complexes present exogenous or endogenous tumor proteins that have been processed into short peptide fragments, typically 13-25 amino acids in length. The recognition of these pMHC II complexes by the T-cell receptor (TCR) of CD4+ T cells is vital for the induction of a sustained anti-tumor immune response, as these helper cells secrete cytokines like IFN-gamma and IL-2 that activate cytotoxic T cells and remodel the tumor microenvironment (Frontiers in Immunology, 2020). Therapeutic approaches targeting these complexes include peptide vaccines, such as UV1 and SurVaxM, and TCR-engineered T-cell therapies designed to specifically bind TAA-MHC II complexes (Journal of Clinical Oncology, 2021). Key challenges in targeting this class include the high degree of HLA polymorphism among patients and the risk of off-target toxicity if the target antigen is present on non-malignant tissues (Journal of Clinical Investigation, 2016). Overall, TAA-MHC II complexes represent a sophisticated target class aimed at leveraging the regulatory and effector power of the helper T-cell compartment.

Other names

MHC class II-restricted tumor antigensHLA class II-presented tumor peptidesTAA-HLA-II complexesTumor-specific MHC II-peptide complexesMHC II-restricted neoantigens

Activation of CD4+ T-helper cells through the recognition of specific tumor-derived peptide-MHC class II complexes, leading to the secretion of Th1 cytokines and the orchestration of a robust, multi-effector anti-tumor immune response (Frontiers in Immunology, 2020).